Protein Production, Structural Biology, and Nucleic Acid Sequencing and Analysis
- Institution
- VERSITI WISCONSIN, INC., WI
- Principal investigator
- Jieqing Zhu
- Funding
- $413K
- Duration
- 2024–2029
Moonbase score
Still being scored
Abstract
CORE B SUMMARY This Program Project focuses on a group of closely related and clinically important antibody-mediated thrombocytopenias in which β3 integrins (αIIbβ3, αVβ3, and single-chain β3 fragments) and platelet chemokines including platelet factor 4 (PF4) and platelet basic protein isoforms (PBPi) are among the target antigens. Purified antibodies of human and mouse origin, and protein antigens including integrins, PF4, PBPi, and their mutants represent essential materials shared among the three Projects for the proposed structural and functional studies. In addition, next-generation sequencing (NGS) is a powerful tool that will be utilized by Projects 2 and 3 to isolate anti-PF4 and anti-PBPi monoclonal antibodies, and investigate the molecular and cellular mechanisms underlying the ontogeny of B cells that generate harmful antibodies resulting in antibody-mediated thrombocyto- penia and associated pathogenesis. The overall goal of Core B is to provide centralized and standardized large-scale antibody and protein production and authentication services, structure-based data interpretation of antibody-antigen interaction and functional assays, as well as centralized NGS and data analysis to each of the Projects in our Program, which should reduce the time and effort, maximize cost savings, ensure data repro- ducibility, cross-validation, and interpretation in parallel and/or complementary studies.
LOADING MOONBASE SCORE
Questions for Versiti Wisconsin, Inc.
Versiti Wisconsin, Inc. hasn't set up its Moonbase portfolio yet, so questions about this research can't be asked here.
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Versiti Wisconsin, Inc.Not yet scored
Non-conventional signaling by α5 integrin in blood and endothelial cells
Jieqing Zhu · $719K · 2024–2028
- NIH · Versiti Wisconsin, Inc.Not yet scored
Structural Transition of Cellular Integrins and Applications Thereof
Jieqing Zhu · $798K · 2016–2028
- NIH · Versiti Wisconsin, Inc.Reviewed
Cytokine regulation of recirculating and tissue-resident memory CD8+ T cells in homeostasis and inflammation
Nicholas N Jarjour · $162K · 2025–2027